Soleno Therapeutics (SLNO) Other Non-Current Liabilities (2013 - 2026)
Soleno Therapeutics (SLNO) reported Other Non-Current Liabilities of $1.4 million for Q1 2026, down 91.98% year-over-year from $17.8 million in Q1 2025, and up 171.43% on a QoQ basis from $525000.0 in Q4 2025.
Soleno Therapeutics (SLNO) has 14 years of Other Non-Current Liabilities data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 91.98% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 91.98% YoY) and the FY2025 annual result came in at $525000.0, down 96.45% from the prior year.
- Other Non-Current Liabilities advanced to $1.4 million in Q1 2026 per SLNO's latest filing, from $525000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $19.5 million in Q3 2025 and bottomed at $271000.0 in Q2 2025.
- The 5-year median for Other Non-Current Liabilities is $9.4 million (2023), against an average of $10.1 million.
- Peak annual rise in Other Non-Current Liabilities reached 48.6% in 2025, while the deepest fall reached 98.01% in 2025.
- Tracing SLNO's Other Non-Current Liabilities over 5 years: stood at $8.8 million in 2022, then jumped by 30.72% to $11.5 million in 2023, then increased by 28.07% to $14.8 million in 2024, then slumped by 96.45% to $525000.0 in 2025, then surged by 171.43% to $1.4 million in 2026.
- Per Business Quant, the three latest SLNO Other Non-Current Liabilities figures stand at $1.4 million (Q1 2026), $525000.0 (Q4 2025), and $19.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.43 Mn |
| Dec 31, 2025 | 525,000.00 |
| Sep 30, 2025 | 19.47 Mn |
| Jun 30, 2025 | 271,000.00 |
| Mar 31, 2025 | 17.76 Mn |
| Dec 31, 2024 | 14.79 Mn |
| Sep 30, 2024 | 14.46 Mn |
| Jun 30, 2024 | 13.59 Mn |
| Mar 31, 2024 | 11.95 Mn |
| Dec 31, 2023 | 11.55 Mn |
| Sep 30, 2023 | 10.47 Mn |
| Jun 30, 2023 | 9.45 Mn |
| Mar 31, 2023 | 9.13 Mn |
| Dec 31, 2022 | 8.84 Mn |
| Sep 30, 2022 | 9.44 Mn |
| Jun 30, 2022 | 9.31 Mn |
| Mar 31, 2022 | 8.69 Mn |
| Dec 31, 2021 | 9.55 Mn |
| Sep 30, 2021 | 12.88 Mn |
| Jun 30, 2021 | 12.33 Mn |
| Mar 31, 2021 | 9.29 Mn |
| Dec 31, 2020 | 10.28 Mn |
| Sep 30, 2020 | 10.14 Mn |
| Jun 30, 2020 | 9.36 Mn |
| Mar 31, 2020 | 6.52 Mn |
| Dec 31, 2019 | 5.94 Mn |
| Sep 30, 2019 | 6.07 Mn |
| Jun 30, 2019 | 6.04 Mn |
| Mar 31, 2019 | 5.86 Mn |
| Dec 31, 2018 | 5.65 Mn |
| Sep 30, 2018 | 5.67 Mn |
| Jun 30, 2018 | -812,000.00 |
| Mar 31, 2018 | -233,000.00 |
| Dec 31, 2017 | 5.08 Mn |
| Sep 30, 2017 | 1.13 Mn |
| Jun 30, 2017 | 1.13 Mn |
| Mar 31, 2017 | 1.20 Mn |
| Dec 31, 2016 | 61,739.00 |
| Sep 30, 2016 | 115,000.00 |
| Jun 30, 2016 | 193,000.00 |
| Mar 31, 2016 | 219,000.00 |
| Dec 31, 2015 | 109,404.00 |
| Sep 30, 2015 | 151,000.00 |
| Jun 30, 2015 | 894,000.00 |
| Mar 31, 2015 | 3.58 Mn |
| Sep 30, 2014 | 3.07 Mn |
| Dec 31, 2013 | 1.46 Mn |